Pfizer (Pfizer) Change In Receivables

: $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1951. Start your Free Trial

Pfizer's change in receivables for the quarter that ended in Dec. 2023 was $0 Mil. It means Pfizer's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Pfizer's change in receivables for the fiscal year that ended in Dec. 2023 was $347 Mil. It means Pfizer's Accounts Receivable declined by $347 Mil from Dec. 2022 to Dec. 2023 .

Pfizer's Accounts Receivable for the quarter that ended in Dec. 2023 was $11,177 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Pfizer's Days Sales Outstanding for the three months ended in Dec. 2023 was 71.58.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pfizer's liquidation value for the three months ended in Dec. 2023 was $-111,046 Mil.

Pfizer Change In Receivables Historical Data

The historical data trend for Pfizer's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-1,124.00

-1,249.00

-3,811.00

261.00

347.00

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-	-	-	-	-

Pfizer Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Pfizer (NYSE:PFE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Pfizer's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	11177	/	14249	*	91
=	71.58

2. In Ben Graham's calculation of liquidation value, Pfizer's accounts receivable are only considered to be worth 75% of book value:

Pfizer's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	12690	-	137213	+	0.75 * 11177	+	0.5 * 10189
=	-111,046

Pfizer Change In Receivables Related Terms

Thank you for viewing the detailed overview of Pfizer's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (Pfizer) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFEB:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Executives

Scott Gottlieb	director	MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff	officer: Executive Vice President	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico	officer: SVP & Controller	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni	officer: Executive Vice President	ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr	officer: Executive Vice President	600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler	officer: Senior Vice President	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten	officer: Senior Vice President	5 GIRALDA FARMS, MADISON NJ 07940
David M Denton	officer: Chief Financial Officer & EVP	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao	officer: Executive Vice President	C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott	officer: Executive Vice President	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson	officer: Executive Vice President	PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie	officer: Executive Vice President	C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman	officer: Senior Vice President	767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang	officer: Group President	235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young	officer: Business Unit President	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017